Lindbrook Capital’s Unity Biotechnology UBX Stock Holding History

Lindbrook Capital’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4	Closed	–	–	2913
2022 Q2	$0	Hold	4	–	–	﹤0.01%	2778
2022 Q1	$0	Hold	4	–	–	﹤0.01%	2617
2021 Q4	$0	Hold	4	–	–	﹤0.01%	2204
2021 Q3	$0	Hold	4	–	–	﹤0.01%	2000
2021 Q2	$0	Hold	4	–	–	﹤0.01%	2003
2021 Q1	$0	Hold	4	–	–	﹤0.01%	1947
2020 Q4	$0	Hold	4	–	–	﹤0.01%	1881
2020 Q3	$0	Hold	4	–	–	﹤0.01%	1843
2020 Q2	$0	Hold	4	–	–	﹤0.01%	1897
2020 Q1	$0	Hold	4	–	–	﹤0.01%	1864
2019 Q4	$0	Hold	4	–	–	﹤0.01%	1554
2019 Q3	$0	Hold	4	–	–	﹤0.01%	1539
2019 Q2	$0	Hold	4	–	–	﹤0.01%	1511
2019 Q1	$0	Hold	4	–	–	﹤0.01%	1506
2018 Q4	$0	Buy	+4	New	+$531	﹤0.01%	1437

Other funds holding UBX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

ACM

Altium Capital Management New York $42M AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lindbrook Capital's UBX Position: Q3 2022 in Review

Lindbrook Capital sold out of Unity Biotechnology (UBX) in Q3 2022, closing a stake of 4 shares.

Lindbrook Capital first reported a position in UBX in Q4 2018 and held it in 15 quarters. The position peaked at $0 in Q2 2022. 72 funds tracked by Wall St. Rank hold UBX as of Q3 2022.

Lindbrook Capital reported no remaining Unity Biotechnology position as of Q3 2022 after selling out during the quarter.
Lindbrook Capital sold 4 Unity Biotechnology shares in Q3 2022.
Lindbrook Capital first reported a position in Unity Biotechnology in Q4 2018 and held it in 15 quarters.
Lindbrook Capital's Unity Biotechnology position peaked at $0 in Q2 2022.
72 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2022.

Based on Lindbrook Capital's 13F filing for Q3 2022, filed 10 Nov 2022.